Viking Therapeutics shares surged after the company reported new VK2735 trial results showing strong weight loss and the possibility of maintaining much of that loss with injections every two weeks or once a month. The less-frequent schedules are important because obesity treatment is long term, and fewer injections may make therapy easier to continue.
VK2735 is an experimental dual GLP-1/GIP receptor agonist. It targets the same broad biological pathways that have made modern obesity drugs a major pharmaceutical market. Viking is developing both injectable and oral versions, but the September update focused on an injectable maintenance study.
What Did the New VK2735 Trial Show?
The study began with 21 weeks of once-weekly VK2735 treatment. Across active-dose groups, average weight loss ranged from about 16% to 19%, compared with roughly 0% for placebo. Viking reported that the reductions were statistically significant and continued through week 21 without a clear plateau.
| Weekly dose | Mean weight change at week 21 | Placebo-adjusted change |
|---|---|---|
| 15 mg | -16.3% | -16.2% |
| 17.5 mg | -17.8% | -17.7% |
| 20 mg | -18.7% | -18.6% |
| 22.5 mg | -17.1% | -17.0% |
The 20 mg group produced the largest mean percentage reduction at week 21. The data also showed broad response rates. In the combined VK2735 groups, 98% of participants lost at least 5% of body weight, 90% lost at least 10%, 65% lost at least 15%, and 32% lost at least 20%.
An exploratory control group continued weekly 17.5 mg dosing beyond the initial period. By week 33, the group had lost about 22% of body weight on a placebo-adjusted basis. Viking said there was still no evidence of a plateau, suggesting that the drug’s effect had not clearly flattened during the measured period.
How Well Did Patients Maintain Their Weight Loss?
The most differentiated part of the VK2735 trial results came after the weekly induction phase. Participants moved to maintenance schedules that included every-other-week injections, monthly injections or placebo. The goal was to test whether patients could preserve earlier weight loss with fewer doses.
Viking reported that participants maintained up to 97% of their prior weight loss after switching to every-other-week dosing for three months. Those moving to monthly dosing maintained up to 90%. The exact result varied by regimen, but both schedules compared favorably with the placebo-maintenance group.
This finding addresses a practical question in obesity care. Losing weight is only one stage. Patients also need a workable way to preserve the result. A maintenance schedule with fewer injections could reduce treatment burden while keeping the biological effect active.
Why Does Monthly Dosing Matter?
Weekly injections are already familiar in the obesity market, but treatment can continue for years. Moving from four injections a month to one could change convenience, adherence and distribution. It may also give physicians more choices when a patient has reached a target and moves from active weight loss to maintenance.
Monthly dosing does not automatically make VK2735 a better product. Larger and longer studies still need to confirm how durable the maintenance effect is across a broader population. The new result matters because it provides clinical evidence for a feature competitors may find difficult to match: strong initial loss combined with flexible maintenance intervals.
Viking also reported favorable tolerability during the maintenance phase. Gastrointestinal adverse-event rates were similar to placebo, and reported events were generally mild. Tolerability matters because nausea, vomiting and other gastrointestinal effects can cause patients to stop GLP-1-based treatment.
How Does VK2735 Compare With Current Obesity Drugs?
| Drug | Developer | Mechanism | Current role |
|---|---|---|---|
| VK2735 | Viking Therapeutics | GLP-1/GIP dual agonist | Experimental; injectable and oral programs |
| Zepbound | Eli Lilly | GLP-1/GIP dual agonist | Approved weekly obesity treatment |
| Wegovy | Novo Nordisk | GLP-1 agonist | Approved weekly obesity treatment |
VK2735 is closest in mechanism to Eli Lilly’s tirzepatide, sold for obesity as Zepbound. The September results do not provide a direct head-to-head comparison, so differences between separate trials should be interpreted carefully. Viking’s clearest angle is the maintenance schedule: it is testing whether a patient can keep much of the initial loss with injections spaced farther apart.
The competitive field also includes next-generation pills, triple agonists and drugs designed to preserve lean mass. That means VK2735’s commercial position will depend on more than headline weight loss. Safety, manufacturing capacity, insurance coverage, dose flexibility and final Phase 3 data will all matter.
What Sent VKTX Stock Up 35%?
VKTX closed near $40.85 on September 22, up about 35.6%. It traded between roughly $31.25 and $45.93, with volume above 41 million shares. The move reflected three pieces of information arriving together.
- Competitive efficacy: Weight loss reached the high teens at week 21 and about 22% in the exploratory longer-treatment group.
- Flexible maintenance: Every-other-week and monthly schedules preserved much of the earlier loss.
- Clean maintenance tolerability: Reported gastrointestinal event rates were similar to placebo during the maintenance phase.
Biotechnology stocks often react sharply to clinical readouts because one dataset can change assumptions about approval odds, market size and partnership value. Readers can see another example of pipeline-driven valuation in Tapbit Learn’s analysis of ABCL stock and AbCellera’s drug pipeline.
What Comes Next for Viking Therapeutics?
Phase 3 injectable program
Viking’s VANQUISH 1 and VANQUISH 2 Phase 3 trials for subcutaneous VK2735 are central to the approval path. Larger trials will provide more information about long-term efficacy and safety.
Oral VK2735
An oral version could reach patients who prefer a pill. Its dose, tolerability, manufacturing economics and efficacy will be evaluated separately from the injectable program.
Maintenance durability
The latest study covered three months of less-frequent maintenance dosing. Investors will look for longer follow-up showing whether the retained weight loss persists.
Stock-linked product identity
VKTX is a Nasdaq-listed biotechnology stock. Tapbit does not have a confirmed VKTX-linked contract in this article. Stock-linked derivatives are different from traditional shares; the Tapbit stock-token guide explains the product distinction.
Follow Event-Driven Markets on Tapbit
Tapbit does not have a confirmed VKTX-linked product in this article. Readers can register on Tapbit, explore the stock-linked futures currently supported, select an available contract, choose an order type and direction, enter the quantity, review margin and order information, and then confirm the order.
VK2735 and VKTX FAQ
What is VK2735?
VK2735 is Viking Therapeutics’ experimental dual GLP-1/GIP receptor agonist for obesity and metabolic disorders.
How much weight did participants lose?
Average weight loss ranged from about 16% to 19% after 21 weeks of weekly treatment. An exploratory weekly-treatment group reached about 22% by week 33.
Can VK2735 be taken once a month?
The drug is still experimental. In the maintenance study, monthly dosing maintained up to 90% of prior weight loss for three months.
Is VK2735 approved by the FDA?
No. VK2735 remains in clinical development and must complete the required trials and regulatory review.
